PREVIOUS
✖
Human monoclonal antibodies in India
May 13 , 2020
1660 days
1023
0
- The Council of Scientific and Industrial Research (CSIR) has sanctioned the project to develop human monoclonal antibodies (hmAbs).
- It will work as a therapy for COVID-19 infections.
- The project will generate hmAbs from patients that are in convalescent phase.
- Monoclonal antibodies will be virus-neutralizing and will be able to block the spread of infection by binding to the virus and making it ineffective.
- Israel was the first to isolate monoclonal antibodies.
- The council has passed the project under its flagship project named the New Millennium Indian Technology Leadership Initiative Programme (NMITLI).
- It is the largest PPP (Public-private partnership) model of Research and Development programme in the country.
- The project will involve Indian Institute of Technology, Indore and National Centre for Cell Science (NCCS), Pune and Bharat Biotech Industry and PredOmix Technologies, Gurugram for a public health emergency.
Leave a Reply
Your Comment is awaiting moderation.